Short Interest in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Decreases By 24.9%

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the recipient of a large decrease in short interest in January. As of January 30th, there was short interest totaling 144,124 shares, a decrease of 24.9% from the January 15th total of 192,015 shares. Based on an average daily volume of 181,961 shares, the short-interest ratio is presently 0.8 days. Currently, 1.0% of the shares of the company are short sold. Currently, 1.0% of the shares of the company are short sold. Based on an average daily volume of 181,961 shares, the short-interest ratio is presently 0.8 days.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a research note on Wednesday, November 19th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $8.33.

Institutional Trading of Kairos Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Kairos Pharma during the 3rd quarter worth approximately $27,000. XTX Topco Ltd acquired a new stake in shares of Kairos Pharma during the second quarter worth $44,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Kairos Pharma during the third quarter worth $54,000.

Kairos Pharma Price Performance

Shares of Kairos Pharma stock traded up $0.00 during trading on Monday, hitting $0.60. The company’s stock had a trading volume of 98,183 shares, compared to its average volume of 134,084. The stock has a market cap of $12.45 million, a price-to-earnings ratio of -1.93 and a beta of 2.28. Kairos Pharma has a 52 week low of $0.40 and a 52 week high of $2.11. The stock has a 50-day moving average price of $0.75 and a two-hundred day moving average price of $1.00.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.